EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2017 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
WHEREAS, effective as of March 27, 2017 (the “Effective Date”), the Company desires to employ the Executive, and the Executive desires to be employed by the Company, upon the terms and subject to the conditions set forth in this Agreement; and
STOCK OPTION AGREEMENTStock Option Agreement • May 10th, 2017 • Impax Laboratories Inc • Pharmaceutical preparations • Delaware
As an inducement material to the decision by you (the “Optionee”) to accept employment with Impax Laboratories, Inc. (the “Company”) and pursuant to your grant notice (the “Grant Notice”), this Stock Option Agreement (the “Agreement”) and that certain Employment Agreement entered into between you and the Company effective as of March 24, 2017 (the “Employment Agreement”), the Company has granted you (the “Optionee”) a nontransferable option to purchase the number of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), indicated in the Grant Notice (collectively, the “Option”). This Option is made and granted as a stand-alone award and is not granted under or pursuant to the Company’s Third Amended and Restated 2002 Equity Incentive Plan (the “Plan”). However, unless otherwise defined herein, capitalized terms in this Agreement shall have the meaning ascribed in the Plan.
AMENDMENT NO. 1 TO CREDIT AGREEMENTCredit Agreement • May 10th, 2017 • Impax Laboratories Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO CREDIT AGREEMENT, dated as of March 27, 2017 (this “Agreement”), by and among IMPAX LABORATORIES, INC. (the “Borrower”), Royal Bank of Canada (“Royal Bank”), as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), and each Lender party hereto.
